Patient characteristics and clinical findings
| No. | Age | Sex | Initial examination | Ancillary tests | Last examination | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VA | AC cells | Posterior findings | CSF cells | HLA-D locus | VA | Posterior findings | Follow up (months) | ||||||||
| RE, LE | RE, LE | ||||||||||||||
| 1 | 37 | F | 20/15, 20/50 | − | SRD both eyes | + | DR 4, 9, 53; DQ 3, 4 | 20/15, 20/20 | mild retinal atrophy both eyes | 42 | |||||
| 2 | 53 | M | 20/35, 20/35 | + | disc oedema, ME both eyes | + | NE | 20/25, 20/25 | sunset fundus both eyes, atrophic spot right eye | 42 | |||||
| 3 | 43 | M | 20/70, HM | + | sunset fundus both eyes | NE | DR 4, 6, 52, 53; DQ 4, 6 | 20/20, CF | sunset fundus both eyes | 7 | |||||
| 4 | 25 | M | 20/200, 20/100 | + | disc oedema, SRD both eyes | + | DR 3, 9 | 20/15, 20/15 | sunset fundus, atrophic spots both eyes | 39 | |||||
| 5 | 44 | F | 20/35, 20/35 | + | SRD both eyes | + | DR 4, 6, 52, 53; DQ 1, 4 | 20/20, 20/20 | mild retinal atrophy both eyes | 8 | |||||
| 6 | 26 | M | 20/100, 20/40 | + | disc oedema, SRD both eyes | + | DR 4, 53; DQ 4 | 20/15, 20/15 | sunset fundus both eyes | 20 | |||||
| 7 | 48 | F | 20/70, 20/15 | − | disc oedema, SRD both eyes | + | DR 4, 9, 53; DQ 3, 4 | 20/20, 20/20 | sunset fundus both eyes | 34 | |||||
| 8 | 48 | M | CF, 20/60 | + | ME and CD both eyes | + | NE | 20/25, 20/30 | sunset fundus, atrophic spots both eyes | 34 | |||||
| 9 | 26 | F | 20/15, 20/60 | + | ME left eye | NE | DR 2, 4, 53; DQ 1, 3 | 20/15, 20/15 | mild retinal atrophy both eyes | 6 | |||||
| 10 | 30 | F | 20/50, 20/20 | + | SRD both eyes | + | DR 4, 9, 53; DQ 3, 4 | 20/15, 20/15 | mild retinal atrophy both eyes | 8 | |||||
| 11 | 57 | M | 20/100, 20/100 | + | sunset fundus both eyes | NE | DR 4, w12 | 20/25, 20/50 | sunset fundus, atrophic spots both eyes | 90 | |||||
| 12 | 40 | F | 20/20, 20/20 | + | SRD both eyes | + | DR 4, 53; DQ 4 | 20/20, 20/20 | mild retinal atrophy both eyes | 26 | |||||
| 13 | 21 | F | 20/70, 20/200 | + | SRD both eyes | NE | DR 2, 9, 53; DQ 1, 3 | 20/20, 20/20 | sunset fundus both eyes | 25 | |||||
| 14 | 63 | F | 20/400, 20/200 | + | SRD, CD both eyes | + | DR 4, 53; DQ 4 | 20/20, 20/15 | sunset fundus both eyes | 20 | |||||
| 15 | 25 | F | 20/50, 20/200 | + | disc oedema, SRD both eyes | + | DR 6, 12, 52; DQ 1, 7 | 20/15, 20/15 | sunset fundus, atrophic spots both eyes | 20 | |||||
| 16 | 46 | M | 20/50, 20/60 | + | disc oedema, SRD both eyes | + | DR 1, 4, 53; DQ 1, 4 | 20/25, 20/25 | sunset fundus both eyes | 16 | |||||
| 17 | 43 | F | 20/30, 20/35 | + | SRD both eyes | + | NE | 20/15, 20/20 | sunset fundus both eyes | 14 | |||||
| 18 | 28 | F | 20/20, 20/250 | + | SRD both eyes | − | DR 4, 9, 53; DQ 3, 4 | 20/15, 20/60 | sunset fundus both eyes | 17 | |||||
VA=best corrected visual acuity; AC=anterior chamber; CSF=cerebrospinal fluid; HLA=histocompatibility leucocyte antigen; SRD=serous retinal detachment; ME=macular oedema; NE=not examined; HM=hand movements; CF=counting fingers; CD=choroidal detachment.
↵Initial examination data are for the acute phase in all cases except for in patients 3 and 11 who presented with persistent anterior segment inflammation bilaterally 6 months and 3 years after the onset of uveitis, respectively.